[1] World Health Organization. Rabies. 2025. https://www.who.int/health-topics/rabies#tab=tab_1. [2025-3-31].
[2] Shi LT, Yu YX. Brief history of development of rabies vaccine for human use in China. Prog Microbiol Immunol 2024;52(1):1 − 8. https://doi.org/10.13309/j.cnki.pmi.2024.01.001.
[3] General Department of the National Disease Control and Prevention Administration, General Office of the National Health Commission. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). 2023. https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_1706569159854649344.html.[2026-4-21].(In Chinese).
[4] World Health Organization. Rabies vaccines: WHO position paper – April 2018. Wkly Epidemiol Rec 2018;93(16):201-19. https://iris.who.int/server/api/core/bitstreams/b3f08b00-3107-4643-a0b2-b473f9599540/content
[5] Zhang XR, Wu ZG, Zhang WS. Adverse reaction caused by rabies vaccine in China: a Meta-analysis. Chin J Epidemiol 2017;38(6):821 − 7. https://doi.org/10.3760/cma.j.issn.0254-6450.2017.06.026.
[6] Li WM, Liu SY, Qian SY, Zhu JH, Selvaraj JN, Zhang XY. Is the rate of adverse reaction to rabies vaccine in China really as the public thinks?—based on a meta analysis. Hum Vaccin Immunother 2021;17(3):714 − 22. https://doi.org/10.1080/21645515.2020.1794218.
[7] Zhang LN, Li KL, Li Y, Fan CX, Li Y, Ren MR, et al. Surveillance of adverse events following immunization in China, 2023. Chin J Vaccines Immun 2025;31(2):121 − 31. https://doi.org/10.19914/j.CJVI.2025021.
[8] Zhang LN, Li Y, Li KL, Li Y, Fan CX, Ren MR, et al. Surveillance of adverse events following immunization in China, 2021-2022. Chin J Vaccines Immun 2024;30(4):470 − 84. https://doi.org/10.19914/j.CJVI.2024079.
[9] Zhang N, Xu XN, Zhang MH, Yu PC, Liu SQ, Liu Q, et al. Rabies surveillance and epidemiological analysis in China, 2019-2023. Chin J Virol 2025;41(3):757 − 64. https://doi.org/10.13242/j.cnki.bingduxuebao.250087.
[10] Moro PL, Woo EJ, Paul W, Lewis P, Petersen BW, Cano M. Post-marketing surveillance of human rabies diploid cell vaccine (Imovax) in the vaccine adverse event reporting system (VAERS) in the United States, 1990‒2015. PLoS Negl Trop Dis 2016;10(7):e0004846. https://doi.org/10.1371/journal.pntd.0004846.
[11] Kang G, Lakhkar A, Bhamare C, Dharmadhikari A, Narwadkar J, Kanujia A, et al. Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure. Lancet Reg Health Southeast Asia 2023;14:100207. https://doi.org/10.1016/j.lansea.2023.100207.
[12] World Health Organization. Global manual on surveillance of adverse events following immunization. Geneva (Switzerland): WHO; 2016. https://www.who.int/publications/i/item/9789241507769.
[13] McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016;137(3):868 − 78. https://doi.org/10.1016/j.jaci.2015.07.048.
[14] Bonetto C, Trotta F, Felicetti P, Alarcón GS, Santuccio C, Bachtiar NS, et al. Vasculitis as an adverse event following immunization - Systematic literature review. Vaccine 2016;34(51):6641 − 51. https://doi.org/10.1016/j.vaccine.2015.09.026.
[15] Verity CM, Greenwood R, Golding J. Long-term intellectual and behavioral outcomes of children with febrile convulsions. N Engl J Med 1998;338(24):1723 − 8. https://doi.org/10.1056/NEJM199806113382403.
[16] Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf 2009;32(4):309 − 23. https://doi.org/10.2165/00002018-200932040-00005.
[17] Chen Y, Zhang JL, Chu XH, Xu YL, Ma FB. Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol 2020;35(4):363 − 70. https://doi.org/10.1007/s10654-019-00596-1.
[18] Chen Y, Ma FB, Xu YL, Chu XH, Zhang JL. Vaccines and the risk of acute disseminated encephalomyelitis. Vaccine 2018;36(26):3733 − 9. https://doi.org/10.1016/j.vaccine.2018.05.063.